Werewolf Therapeutics
HOWL
42 hedge funds and large institutions have $3.75M invested in Werewolf Therapeutics in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 11 closing their positions.
350% more call options, than puts
Call options by funds: $27K | Put options by funds: $6K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
7.43% less ownership
Funds ownership: 28.84% → 21.41% (-7.4%)
13% less funds holding
Funds holding: 48 → 42 (-6)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
68% less capital invested
Capital invested by funds: $11.7M → $3.75M (-$7.91M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.09M |
| 2 |
VA
Verdad Advisers
Boston,
Massachusetts
|
+$194K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$134K |
| 4 |
Jane Street
New York
|
+$103K |
| 5 |
Renaissance Technologies
New York
|
+$96.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.62M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$688K |
| 3 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$469K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$64.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$32.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| – | -$2.82K | -3,384 | Closed |
|
52
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$167 | -200 | Closed |
|
|
AAP
53
Arax Advisory Partners
Denver,
Colorado
| – | -$32 | -12 | Closed |
|
HOWL Hedge Fund Activity: Q2 2026 in Review
42 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q2 2026, worth a combined $3.75M — down 68% from $11.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of HOWL and 9 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $1.09M. The largest seller was RA Capital Management, cutting an estimated $2.62M.
- 42 institutional investors held Werewolf Therapeutics (HOWL) as of Q2 2026, down from 48 in Q1 2026.
- Funds reported $3.75M of Werewolf Therapeutics stock for Q2 2026, down 68% quarter-over-quarter.
- 9 funds opened new Werewolf Therapeutics positions in Q2 2026 and 11 closed out, a net change of -2 holders.
- The largest Werewolf Therapeutics buyer in Q2 2026 was Balyasny Asset Management, an estimated $1.09M added.
- The largest Werewolf Therapeutics seller in Q2 2026 was RA Capital Management, an estimated $2.62M sold.
Based on aggregated 13F filings for Q2 2026.